Answers are grounded in this paper and cite their sources.
Achieving efficient radiolabeling and targeted delivery is essential to maximize therapeutic efficacy and reduce systemic toxicity. Herein, we report a novel radionuclide-delivery platform based on hybrid membranes derived from fusing liposome with statherin engineered macrophage membranes and gastric cancer cell (MFC) membranes. The obtained 131 I-lipo@[RAW-MFC] nanoparticles ( 131 I-Lip RM ) exhibit high-yield, stable radiolabeling and homologous tumor targeting. Using a gastric cancer model, we assess the biodistribution and therapeutic potential of 131 I-Lip RM alone and combine with anti-PD-L1 therapy. 131 I-Lip RM show favorable pharmacokinetics and efficient tumor localization, inducing significant tumor cell damage and growth suppression. Furthermore, the combination of 131 I-Lip RM with anti-PD-L1 therapy has synergistically enhanced T cell-mediated immune responses, promoted CD8 + T cell infiltration, and prolonged survival relative to monotherapies. These findings demonstrate that the 131 I-Lip RM platform enables precise radionuclide delivery and potentiates antitumor immunity through PD-L1 blockade, presenting a promising avenue for radio-immunotherapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: